Abstract
Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative stress play key roles in the development and/or progression of IR induced by obesity. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily; PPAR agonists can improve IR by regulating glucose and lipid metabolisms, and by inhibiting inflammatory and oxidative stress responses. In the article, we will review the pathogenesis of obesity-induced IR, its therapeutic targets: PPARα/γ, and discuss the signal transduction pathways through which these drugs exert therapeutic effects.
Keywords: obesity, insulin resistance, PPARα/γ
Current Signal Transduction Therapy
Title:Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ
Volume: 7 Issue: 2
Author(s): Zhigang Qi and Meilin Xie
Affiliation:
Keywords: obesity, insulin resistance, PPARα/γ
Abstract: Insulin resistance (IR) is defined as a decreased response of peripheral tissues to insulin. It is a common cause of cardiovascular and hepatic diseases, and often precedes the onset of hyperglycemia and predicts the development of type 2 diabetes. Free fatty acids (FFA), inflammation and oxidative stress play key roles in the development and/or progression of IR induced by obesity. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily; PPAR agonists can improve IR by regulating glucose and lipid metabolisms, and by inhibiting inflammatory and oxidative stress responses. In the article, we will review the pathogenesis of obesity-induced IR, its therapeutic targets: PPARα/γ, and discuss the signal transduction pathways through which these drugs exert therapeutic effects.
Export Options
About this article
Cite this article as:
Qi Zhigang and Xie Meilin, Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ, Current Signal Transduction Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157436212800376717
DOI https://dx.doi.org/10.2174/157436212800376717 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Syndrome and Aging: Calcium Signaling as Common Regulator
Current Diabetes Reviews 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Myocardial ‘No-Reflow’ Prevention
Current Vascular Pharmacology von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Quantitative Structure-Activity Relationship Studies on Matrix Metalloproteinase Inhibitors: Hydroxamic Acid Analogs
Medicinal Chemistry Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry The Patented Uses of D-Ribose in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Assessment and Management of Volume Overload Among Patients on Chronic Dialysis
Current Vascular Pharmacology An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Current Drug Targets Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates
Recent Patents on Biotechnology Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology The Zebrafish as a Novel Tool for Cardiovascular Drug Discovery
Recent Patents on Cardiovascular Drug Discovery CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research